Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (4)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
Historical 2019 reference; renal bands retain the book's own method labels.
Renal measure
Not specified; verify before use
Source revision
Not established
Retrieved
2026-09-05 (not the revision date)
The U.S. FLOMAX label has not studied ESRD below CrCl 10 mL/min/1.73 m2; the handbook is not independent clinical-trial confirmation of dialysis safety.
Historical renal bands
At GFR 20-50 and 10-20 mL/min the book retains normal dosing; below 10 it retains normal dosing with caution. The referenced normal dose is 400 micrograms after breakfast.
Historical renal-replacement guidance
APD/CAPD and HD: described as not dialysed, using the <10 band. HDF/high-flux: removal unknown, same band. CAV/VVHD: described as not dialysed, using 10-20. The book emphasizes lack of studies below 10.
Source revision: Not established | Retrieved: 2026-09-05. Retrieval date is not the revision date.
Source:
Scope: Historical handbook facts locally summarized; not a current U.S. label or a modern CRRT protocol. GlobalRPh v7.4.
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
Source scope / renal recommendation differences
Flomax - product and source limitations
Check orthostatic symptoms. The renal statement does not establish a dialysis regimen.
How to use this: Apply only to the stated formulation, indication and renal population.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
NIH/NLM DailyMed - U.S. prescribing information · Adult oral BPH product.
Renal method: Not specified in this summary. Source date: Retrieved: 2026-09-05
Source-read local summary; source-specific recommendations are not automatically interchangeable.
Adult regimen
Start 0.4 mg once daily, about 30 minutes after the same meal each day. If the response is inadequate after 2-4 weeks, 0.8 mg daily may be used. After an interruption of several days, restart at 0.4 mg daily. Swallow capsules intact.
tamsulosin-capsules:dm-6771ad8e-ac92-4aec-b484-5d8350a353f8-1 · Source locator: 2 Dosage and Administration
Renal statement and uncertainty
The label requires no renal dose adjustment. End-stage disease with creatinine clearance <10 mL/min/1.73 m2 was not studied. A separate dialysis regimen is not established by that statement.
Tamsulosin capsules require no renal adjustment in the studied population. Patients with CrCl below 10 mL/min have not been studied. Check orthostatic symptoms. The renal statement does not establish a dialysis regimen.
Renal method: Use the renal measure explicitly present in the RX passage. Source date: Mirror revision not established in the reviewed passage. Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
UK Renal Pharmacy Group / Ashley and Dunleavy / CRC Press · Historical 2019 reference; renal bands retain the book's own method labels.
Renal method: Not specified in this summary. Source date: Not established Retrieved: 2026-09-05
Historical handbook facts locally summarized; not a current U.S. label or a modern CRRT protocol.
Historical renal bands
At GFR 20-50 and 10-20 mL/min the book retains normal dosing; below 10 it retains normal dosing with caution. The referenced normal dose is 400 micrograms after breakfast.
tamsulosin-capsules:rdh5-960-1 · Source locator: Dose in normal renal function; Dose in renal impairment
Historical renal-replacement guidance
APD/CAPD and HD: described as not dialysed, using the <10 band. HDF/high-flux: removal unknown, same band. CAV/VVHD: described as not dialysed, using 10-20. The book emphasizes lack of studies below 10.
tamsulosin-capsules:rdh5-960-2 · Source locator: Dose in renal replacement; Other information
Source-specific limits
The U.S. FLOMAX label has not studied ESRD below CrCl 10 mL/min/1.73 m2; the handbook is not independent clinical-trial confirmation of dialysis safety.
Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page 960; PDF page 979
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Additional summaries stored on this page: 2 official-label, 1 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.
